Open AccessPegvisomant in combination with long-acting somatostatin analogues in acromegaly: the role of the GH receptor deletion of exon 3
Author(s) -
Sanne Franck,
A. J. van der Lely,
Patric J. D. Delhanty,
Jens Otto Lunde Jørgensen,
Sebastian Neggers
Publication year - 2015
Publication title -
european journal of endocrinology
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 1.897
H-Index - 148
eISSN - 1479-683X
pISSN - 0804-4643
DOI - 10.1530/eje-15-0519
Subject(s) - pegvisomant , acromegaly , endocrinology , medicine , somatostatin , exon , somatostatin receptor , somatostatin receptor 3 , somatostatin receptor 2 , growth hormone , biology , hormone , genetics , gene
Doses of the GH receptor (GHR) antagonist pegvisomant (PEGV) that normalize insulin-like growth factor 1 (IGF1) levels vary widely among acromegaly patients. Predictors for PEGV response are baseline IGF1 levels, sex, body weight and previous radiotherapy. A GHR polymorphism lacking exon 3 (d3-GHR) is frequent in the general population. The influence of d3-GHR on PEGV responsiveness in acromegaly is unclear.
Accelerating Research
Robert Robinson Avenue,
Oxford Science Park, Oxford
OX4 4GP, United Kingdom
Address
John Eccles HouseRobert Robinson Avenue,
Oxford Science Park, Oxford
OX4 4GP, United Kingdom